Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Gross Margin came in at 92.99% in Q1 2026, down 4494.0% YoY from 2.12% in Q1 2025, and down 255.41% on a QoQ basis from 59.83% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 6 years of Gross Margin data on file, last reported at 92.99% in Q1 2026.
- Quarterly Gross Margin fell 4494.0% year-over-year to 92.99% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.22% (up 72.0% YoY) and the FY2025 annual result came in at 4.99%, down 1812.0% from the prior year.
- Gross Margin retreated to 92.99% in Q1 2026, from 59.83% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 59.83% in Q4 2025 to a low of 183.81% in Q3 2025.
- A 5-year average of 26.59% and a median of 3.27% in 2023 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 24127 bps in 2025, down 23750 bps in 2025.
- Tracing RXRX's Gross Margin over 5 years: stood at 20.74% in 2022, then sank by 55 bps to 9.27% in 2023, then sank by 2056 bps to 181.43% in 2024, then jumped by 133 bps to 59.83% in 2025, then tumbled by 255 bps to 92.99% in 2026.
- The last three Gross Margin figures came in at 92.99% (Q1 2026), 59.83% (Q4 2025), and 183.81% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -49.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.82% |
| Mar 31, 2026 | -92.99% |
| Dec 31, 2025 | 59.83% |
| Sep 30, 2025 | -183.81% |
| Jun 30, 2025 | -4.88% |
| Mar 31, 2025 | -48.04% |
| Dec 31, 2024 | -181.43% |
| Sep 30, 2024 | 53.69% |
| Jun 30, 2024 | 36.19% |
| Mar 31, 2024 | 19.05% |
| Dec 31, 2023 | 9.27% |
| Sep 30, 2023 | -3.27% |
| Jun 30, 2023 | 14.84% |
| Mar 31, 2023 | -2.59% |
| Dec 31, 2022 | 20.74% |
| Sep 30, 2022 | -17.09% |
| Jun 30, 2022 | -85.39% |
| Mar 31, 2022 | -46.24% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |